25 февраля, 2024

PSE: a new test for prostate cancer

Introduction of antigen prostate-specific (PSA) in the screening and diagnosis of Prostate Cancer (CaP) represented, from the 90s of the last century to the early 2000s, a paradigm shift in the management of the disease, resulting in an increase in the incidence and prevalence of cases due to early diagnosis of CaP, including «indolent» forms […]

25 января, 2024

AIFA updates the Transparency Lists to 15 December 2022

AIFA Agenzia Italiana del Farmaco AIFA updates the Transparency Lists to In order to allow the Regions and Autonomous Provinces a homogeneous application of the provisions of art. 9, paragraph 5 of Law no. 178 of 8 August 2002, the Italian Medicines Agency publishes, pursuant to AIFA Directorial Determination no. 166 of the Official Gazette […]

19 января, 2024

ASH 2022 – New insights into lymphoma microenvironment pave the way for more effective immunotherapy

Insight Noncancerous cells and their soluble factors play an important role in resistance to immunotherapy. The composition and activity of tumor microenvironment (TME) can be used as targets of therapies. CD19 T cells with chimeric antigen receptor (CAR) therapy has revolutionized the treatment of the most severe and refractory cases of lymphoma, but more than […]

9 декабря, 2023

Closure of Managed Entry Agreements (MEA) Registries Iclusig

Users of monitored Drug Registries are advised that, as of , the procedures for implementing risk-sharing agreements, i.e. Managed Entry Agreements (MEAs), are no longer active for registries for the following therapeutic indications: is indicated in adult patients with: chronic phase myeloid leukemia with Philadelphia chromosome positive (CML) Ph ), accelerated or blastic resistant or […]

29 ноября, 2023

EMA recommends approval of tremelimumab

The At its meeting in December 2022 a  Recommendation for approval for Tremelimumab (Imjudo, AstraZeneca): The monoclonal antibody should be used in combination with durvalumab as first-line treatment for adults with advanced or unresectable hepatocellular carcinoma. This full text is unfortunately reserved for medical professionals You have reached the maximum number of articles for unregistered visitors […]

2 октября, 2023

Taking care of those who care

Regione Emilia Romagna (Agenzia Sanitaria e Sociale Regionale) Taking care of those who care The narrative in the training course at the time of Covid-19 The dossier, starting from a methodological choice, that of the narrative approach, describes the origins, methods, objectives and techniques of the training course «Taking care of those who care: laboratory […]

30 сентября, 2023

ASH 2023 – The science behind the first CAR-T-cell therapy against T-ALL

Key messages In a world-first application of CAR T cell therapy, base-edited T cells were administered for the first time to a patient with relapsed T-cell leukemia. For gene editing, a base editing approach was used to prevent the DNA damage that occurs with other gene-editing methods. A patient with relapsed T-cell leukemia was successfully […]

18 июля, 2023

Lauterbach and gematik: Opt-out ePA is coming

Berlin (pag) – The electronic patient record (EHR) with opt-out solution can come. gematik receives a resolution from its shareholders to prepare the introduction. Meanwhile, Federal Health Minister Prof. Karl Lauterbach (SPD) announces a draft law. Until the introduction of the opt-out EHR, however, the National Agency for Digital Medicine still allows itself leeway.»This solution […]